Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

NCT02454842 is registered in ClinicalTrials.gov with Rain Oncology Inc as lead sponsor.

NCT NCT02454842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor
Lead sponsor
Rain Oncology Inc
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2015
Completion date
January 31, 2017
Enrollment
21 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, non-squamous nsclc, nsclc